Investor Relations

Bio Details

Gautam Patel

Mr. Gautam Patel was appointed to our Board on October 2020. Mr Patel serves as Managing Director of Tarsadia Investments, a private investment firm based in Newport Beach, California, which he joined in 2012. In that role, Mr. Patel has led a team of investment professionals to identify, evaluate, and execute principal control equity investments across sectors including life sciences, financial services, and technology. Prior to joining Tarsadia in 2012, Mr. Patel served as Managing Director at Lazard, where he led financial and strategic advisory efforts in sectors including transportation and logistics, private equity, and healthcare. Mr. Patel joined Lazard as an associate in 1999, after graduating from business school. From 1994 to 1997, Mr. Patel was an Analyst at Donaldson, Lufkin & Jenrette, where he worked on mergers and acquisitions as well as high-yield and equity financings. Mr. Patel is currently a Board Member of Amneal Pharmaceuticals (NYSE: AMRX) as well as several private companies including Kashiv Biosciences, Asana Biosciences, Prolong Pharmaceuticals, LERETA and AIONX Antimicrobial Technologies. Mr. Patel also serves on the board of Casita Maria Center for Arts and Education, a New York based non-profit organization which aims to empower children through arts based education. Mr. Patel received a B.A. from Claremont McKenna College, a B.S. from Harvey Mudd College, an MSc from the London School of Economics and an MBA from the University of Chicago. Mr. Patel currently serves as a member of our Audit Committee.
Financial Expert
Safe Harbor Disclaimer

Certain matters discussed herein, with the exception of historical matters, are forward-looking statements which involve risks and uncertainties. Actual results may differ materially from these statements as a result of changes in external competitive market factors, unanticipated changes in the company's industry, or the economy in general, as well as various other factors, including those discussed herein and those set forth in the Company's most recent Annual Report on Form 10-K.

Shareholder Tools
Print Page
E-mail Page
RSS Feeds
Email Alerts